影响儿童非特异性慢性咳治疗行为性咳抑制治疗的因素
Robert Brinton Fujiki1, Miranda L Wright2,3, Amanda E Fujiki4
1Department of Surgery, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Pediatric pulmonology
|September 22, 2023
概括
行为性咳抑制疗法 (BCST) 有效地治疗儿童慢性咳,通常在短短几次治疗中消除症状. 这种低风险疗法对患有非特异性咳的儿科患者显示出有希望的结果.
科学领域:
- 儿科耳鼻喉科 儿科耳鼻喉科
- 语音语言病理学 语言病理学
- 行为治疗是一种行为疗法.
背景情况:
- 慢性非特异性咳,也称为滴滴咳,在儿童中很常见.
- 行为性咳抑制疗法 (BCST) 是一种常见的治疗方法,但其有效性和持续时间尚未得到充分证实.
- 这项研究旨在评估儿科BCST结果并确定预测因素.
研究的目的:
- 确定BCST在改善儿童慢性咳方面的疗效.
- 确定预测所需的BCST会话数量的因素.
- 在儿科患者中描述咳特征和相关的并发症.
主要方法:
- 追溯观察队列研究.
- 从151名在儿童耳鼻喉科诊所接受治疗的儿童的电子病历中提取的数据.
- 包括咳特征,病史,BCST细节和结果.
主要成果:
- 大多数咳都是干燥的,往往先有,并且平均持续19个月.
- 观察到的并发病率很高:反流 (62.3%),一般焦虑障碍,喘 (22.1%),睡眠呼吸障碍 (19.2%).
- 在平均1.7个疗程内,BCST在92.5%的患者中减少了咳;行为健康诊断和ILS症状预测了更多的疗程.
结论:
- BCST似乎是小儿慢性非特异性咳的低风险和有效治疗方法.
- 随机临床试验的进一步调查是有必要的.
- 了解并发症和咳特征可以为治疗方法提供信息.
相关概念视频
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
318
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
318
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
COPD: Management Using Bronchodilators and Corticosteroids
236
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
236
Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
Drugs Used in Lower Respiratory Disorders: Overview
474
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
474
Drugs Used in Upper Respiratory Disorders: Overview
279
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
279


